Abstract-Nanomedicine is an emerging field that integrates nanotechnology, biomolecular engineering, life sciences and medicine; it is expected to produce major breakthroughs in medical diagnostics and therapeutics. Nano-scale structures and devices are compatible in size with proteins and nucleic acids in living cells. Therefore, the design, characterization and application of nano-scale probes, carriers and machines may provide unprecedented opportunities for achieving a better control of biological processes, and drastic improvements in disease detection, therapy, and prevention. Recent advances in nanomedicine include the development of nanoparticle (NP)-based probes for molecular imaging, nano-carriers for drug/gene delivery, multifunctional NPs for theranostics, and molecular machines for biological and medical studies. This article provides an overview of the nanomedicine field, with an emphasis on NPs for imaging and therapy, as well as engineered nucleases for genome editing. The challenges in translating nanomedicine approaches to clinical applications are discussed.
INTRODUCTION
Recent advances in nanotechnology provide new abilities to measure, control and manipulate matter (including soft matter) at the nano-scale that is unthinkable with conventional tools. As an emerging field in biomolecular engineering and molecular medicine, nanomedicine focuses on the development and application of engineered nano-scale (1-100 nm) materials, structures and devices for better diagnostics of, and highly specific medical intervention in curing, human diseases. 153 Owing to the size-compatibility of nano-scale structures with proteins and nucleic acids in living cells, nanomedicine approaches have the potential to provide unprecedented opportunities for achieving a better control of biological processes, and drastic improvements in disease detection, therapy, and prevention, thus revolutionizing medicine. Over the last 15 years or so, significant efforts have been made to develop nanomedicine based approaches, and many potential applications of nanomedicine have been, or are being, explored, including nanoparticle (NP)-based molecular imaging probes for biological studies and disease detection (Figs. 1a-1c); nanocarriers for targeted in vivo drug/gene delivery for more efficient therapy (Figs. 1d and 1e); NPs as direct therapeutic agents; and nuclease-based biological nanomachines for genome editing (Fig. 1f) . For basic biological studies, the development of new nano-scale tools and devices have the potential to permit imaging of cellular structures at the nano-scale, rapid measurement of the dynamic behavior of protein complexes and molecular assemblies in living cells and animals, and a better control of intracellular machinery. It is expected that the multifunctional, targeted NPs are capable of overcoming biological barriers to deliver therapeutic agents preferentially to diseased cells and tissues at high local concentrations, resulting in much enhanced efficacy and reduced toxicity. Nanomedicine approaches have the potential to allow clinicians to detect a disease in its earliest, most easily treatable, presymptomatic stage, and provide real-time assessments of therapeutic and surgical outcomes. Nano-scale tools may also be used to quickly identify new disease targets for drug development and predicting drug resistance.
In this review, emphasis is placed on NP-based molecular imaging probes, multifunctional NPs, and the design and validation of engineered nucleases for genome editing. The challenges in translating nanomedicine approaches to clinical applications are discussed. Due to space limitations, this is not intended to be a compre-hensive review, but rather a review of selected research topics in nanomedicine. Other recent reviews of nanomedicine can be found in the literature. 23, 82, 106 
INORGANIC NPS
Many studies in nanomedicine involve the development and application of NPs, including organic and inorganic NPs. Attention here is placed primarily on inorganic NPs; reviews of organic NPs can be found elsewhere. 16, 24, 41, 65, 92, 118, 131 Inorganic NPs are typically made of metal, metal oxide, semiconductor, or rare-earth element. They often possess unique electric, magnetic, optical and plasmonic properties due to the quantum mechanical effects at nanometer scales. 2 Due to significant progress in nanocrystal synthesis over the past decade or so, for most NP systems, their chemical composition, size, shape and other physical properties can be well controlled. 18, 46, 75, 166 Quantum Dots
Perhaps the most extensively studied NP system to date is quantum dots (QDs), especially fluorescenceemitting semiconductor QDs, 3 which usually have a core-shell structure such as CdSe core with ZnS shell (Fig. 2a) . Semiconductor QDs, typically 2-10 nm in diameter, have exceptionally bright fluorescence emission; their emission peaks are red-shifted as the size of QDs increases (Fig. 2a) . The optical properties of QDs are the results of quantum confinement of valence electrons at nanometer scales; 2 their fluorescence emission wavelengths rely on the energy band gap determined by the size and compositions of the QD. 98 In contrast to organic fluorophores, QDs are very photostable, their emission peaks are narrow, with absorption spectra range from UV to visible wavelength. Therefore, multiple QDs with different emission wavelengths can be excited simultaneously upon UV excitation, facilitating multicolor imaging. Further, QDs have Stokes shifts (separation between excitation and emission peaks) as large as 300-400 nm. 50 This reduces interference from tissue autofluorescence in biological specimens, which may bury signals from an organic dye. However, semiconductor QDs are often toxic; concerns over the in vivo toxicity have prompted search for biocompatible QDs, such as InP/ZnSe and InP/ZnS QDs.
14,64 (Fig. 2b) , and to a lesser extent of elementary iron and other magnetic elements. 75, 139 With sizes <20 nm, certain magnetic NPs become superparamagnetic at room temperature. 85 Without an external magnetic field, neighboring superparamagnetic NPs are free of interparticle magnetic interactions, which is critical for the colloidal stability of the NP. However, when an external magnetic field is applied, the magnetic moment of the NPs will align with the applied field and reach saturation at relatively low field strength. Magnetite (Fe 3 O 4 ) and maghemite (c-Fe 2 O 3 ), owing to their excellent biocompatibility, are the most common types of materials in generating superparamagnetic NPs. Superparamagnetic NPs of materials that have higher saturation magnetization have also been developed, including elementary iron, cobalt or iron oxide doped with manganese (Fig. 2b) . 76, 88 Superparamagnetic iron oxide NPs (SPIOs), mostly as a T 2 contrast agent in magnetic resonance imaging (MRI), have the potential to significantly improve the sensitivity of disease detection. 29 The T 2 relaxivity of SPIOs is determined by their magnetic moment and coating conformation, which are in turn controlled by the material and size of the core and coating layer, and the density of the coating molecules on NP surface. 88, 144 In general, SPIOs with higher magnetization, larger core size and thinner surface coating have higher T 2 relaxivity. In particular, SPIOs with large size and high magnetization can have a T 2 relaxivity about two orders of magnitude higher compared with the clinically used first-generation SPIOs on a per-particle basis, 144 therefore holding a great promise in MRIbased molecular imaging. Further, the T 2 relaxivity of magnetic NPs increases upon aggregation, a phenomenon referred to as ''magnetic relaxation switch''. 113 Accordingly, an approach to achieve high T 2 relaxivity is to generate NPs with multiple magnetite cores. 111 
Magnetic NPs

Magnetic
Gold NPs
The most common type of gold NPs is gold nanosphere (Fig. 2c) , which exhibits an intense ruby color in aqueous solutions. The intriguing optical properties of gold NPs arise from localized surface plasmon resonance (LSPR), whereas valence electrons in gold NPs oscillate coherently with incident light at specific frequency. 11 Part of the energy absorbed by gold NPs is emitted in the form of scattered light, which is the basis of many gold NP-based optical imaging. 71 The rest of the energy decays in a non-radiative form, i.e., being converted into heat. Gold nanospheres with a wide range of sizes mainly absorb light at~520 nm wavelength, at which light is rapidly attenuated by the tissue. For in vivo applications, the absorption peak should fall within the optical window of human tissues (650-1300 nm) so that the incident light could penetrate deeply. 147 The absorption spectrum of gold NPs can be tuned by changing their geometry. 119 For example, in gold nanorods (Fig. 2c) , LSPR occurs in two directions along the short and the long axis. The frequency of oscillation along the long axis is redshifted from visible to the near infrared (NIR) region as the aspect ratio of nanorods increases. 69 Other gold nanostructures with tunable LSPR frequency are gold nanocages (Fig. 2c ) and gold nanoshells (Fig. 2d) , of which the absorption spectra change with the overall size, the thickness of the shell (nanoshell) or the wall (nanocage). 58, 134 Further, gold nanoshells and nanostars ( Fig. 2c) with the NIR photothermal property are ideal agents for photothermal therapy. 36, 63, 124 Aggregated gold nanospheres also exhibit significant NIR absorption as a result of coupled plasmon resonance. This has been used to create nanostructures with the NIR photothermal property for in vivo applications. 
NP-BASED PROBES FOR MOLECULAR IMAGING AND BIOMOLECULE DETECTION
One of the most fruitful areas of nanomedicine is molecular imaging using NP probes, including QDs, magnetic NPs and gold NPs. NPs possess unique characteristics that make them well suited as probes for molecular imaging. 89 NPs, including metal, metal oxide and semi-conductor NPs can be synthesized in a systematic fashion to have precise diameter with narrow size distributions. As NPs become smaller, their surface area to volume ratio increases significantly. Engineering of NP surface chemistry allows the surface area to be decorated with therapeutic molecules, imaging agents, targeting ligands, or nucleic acids. To perform NP-based in vivo imaging of molecular markers associated with disease development, the NPs must be functionalized with specific targeting ligands. 17 Distinct ligands and reporters can be attached to a single NP to allow multiplexing and multifunctionality. A single NP can be conjugated with a large number of targeting ligands, increasing the affinity of the NP to its biological target through multivalency. Further, a NP can be conjugated with a large number of reporter molecules (e.g., fluorophores, radiotracers), increasing signal-to-noise ratio in imaging applications. Described below are specific examples of NP-based molecular imaging probes, more comprehensive reviews in this area can be found in the literature.
Gold NPs for Imaging Applications
Gold NPs, including nanospheres, nanoshells, nanorods and nanocages, can be used as contrast agents in photoacoustic imaging. 95, 156, 169, 170 Gold NPs scatter light strongly at their LSPR frequency and thus have broad applications in optical imaging. 70 Furthermore, gold NPs increase local electromagnetic field due to LSPR. As a result, the signals of fluorophores and Raman reporters attached to gold surface can be drastically enhanced. 120 In in vivo applications, gold NPs that scatter NIR light can provide good contrast for optical coherence tomography. 55 Gold nanospheres and gold nanorods have also been used as contrast agents in computed tomography (CT), taking advantage of the high material density and high atomic number of gold. 116, 151 Gold nanoshells and nanocages, even without targeting, can be used as blood pool contrast agents to enhance the visualization of vasculature in vivo (e.g., in the rat brain).
156,169
QDs for Imaging Applications
Since QDs were first rendered water-soluble in 1998 thereby making them relevant for biological studies, 13, 19 they have been applied to cell tracking studies, 52, 152 cancer imaging, 50, 60 flow-cytometry, 22 and labeling of membrane proteins. 10, 67 The applications of QDs have also been extend to fluorescence-based detection of enzymatic activities, particularly when QDs are utilized as either a donor or an acceptor for fluorescence (or Fo¨rster) resonance energy transfer (FRET). 21, 28, 99, 168, 171 For biological applications, it is necessary to coat QDs, making them water-soluble and functionalizable while avoiding deleterious effects on the optical properties. 44, 163 Strategies have been devised using direct adsorption of dihydrolipoic acid on the surface (leading to negative charges), and then electrostatic selfassembly to positively charged proteins. 56, 73 A novel approach is based on the adsorption of bifunctional ligands such as mercaptoacetic acid, mercaptosuccinic acid, dithiothreitol, glutathione or histidine directly to the QD surface. 20 Other strategies employ hydrophilic organic dendron ligands, 155 and micellular encapsulation using phospholipids. 44 Importantly, amphiphilic polymer coated QDs conjugated to streptavidin have become commercially available. 163 
QD-Fluorescent Protein FRET Probe for pH Sensing
QDs make excellent FRET donors because of their characteristic excitation and emission spectra, exceptional brightness and high quantum yields, and the ability to bind multiple acceptor molecules. A particular class of QD-based FRET probes is composed of multiple fluorescent proteins (FPs) as FRET acceptors conjugated to a QD donor. Since the polypeptide sequence of a FP can be genetically modified to include structural and functional elements necessary for protein purification, signal transduction, and probe assembly, as well as intracellular delivery and localization, the use of FPs as FRET acceptors offers clear advantages. For example, standard molecular biology techniques can easily be used to modify the FPs to include a tag for effective conjugation, and a variety of amino acid sequences can be used as linkers between the protein bulk and the tag, adding to the functionality of the QD-FRET probe (such as a cleavage sequence for a protease). The variety of GFPlike FPs now available provides a wide range of possible FP acceptors; they can be readily expressed in E. coli in large quantities. QD-FP FRET pairs exhibit high energy transfer efficiencies and enable ratiometric measurements, resulting in heightened sensitivity by eliciting opposing changes in fluorescence emission at two wavelengths, while maintaining an internal control at an isosbestic point. 38 A specific application of the QD-FP FRET probes is the intracellular pH measurement in biological and disease studies. Intracellular pH (pH i ) plays a critical role in the physiological and pathophysiological processes of cells, 15 and fluorescence imaging using pHsensitive indicators can provide a powerful tool to assess the pH i of intact cells and sub-cellular compartments. As an example, shown in Fig. 3a is the QD-based ratiometric pH sensor comprised of a carboxyl-functionalized QD as donor and pH-sensitive mOrange FPs as accepters. 39 Titration of the QD-FP probes showed that FRET between the QD and multiple FPs modulates the FP/QD emission ratio, exhibiting a >12-fold change between pH 6 and 8 (Fig. 3b) . The QD-FP probes can dramatically improve the sensitivity and photostability compared to BCECF, the most widely used fluorescent dye for pH imaging. 39 Further, the QD-FP probes facilitated the visualization of the acidification of endosomes in living cells following polyarginine-mediated uptake. Potential applications of the QD-FP FRET probes include tracking the endosomal release of nanocarriers for drug/gene delivery, and monitoring pH and/or metal ion concentration in both the intracellular and extracellular environment.
SPIO-Based Imaging Contrast Agents
NPs are a very promising platform as MRI and PET contrast agent for in vivo molecular imaging. For example, compared to gadolinium-based MRI contrast agents, NP-based MRI contrast agents usually circulate in the blood for longer periods of time, and each NP may generate signal contrast several orders of magnitude higher than a gadolinium chelate, thus offering greater sensitivity with reduced side-effects. 165 Perhaps one of the most promising NP systems is SPIOs. 7, 154 SPIOs can induce an increased T 2 relaxivity in MRI, which is determined by the translational diffusion of water molecules in the inhomogeneous magnetic field surrounding the SPIO. 12, 53, 54 In addition, iron oxide has little toxicity for in vivo applications. These features make SPIOs an appealing MRI contrast agent for the detection and diagnosis of human diseases. 88, 101, 104, 161 For biomedical applications, the hydrophobic nanocrystal core of a SPIO is typically encapsulated with amphiphilic polymers such as PoloxamerÒ, PoloxamineÒ and lipid-PEG copolymer. 112, 146, 173 A variety of SPIOs with different cores and surface coatings have been developed for imaging tumors and metastatic lymph nodes. 79, 88, 107, 158, 167, 173 SPIOs can accumulate in the tumor by enhanced permeability and retention effects, which facilitate tumor detection in tissues or organs that normally do not retain SPIOs.
Typically SPIOs can only provide a dark contrast in MRI, which is difficult for quantitative determination of the contrast due to local NP accumulation. In contrast, NPs conjugated with Mn 2+ or Gd 3+ chelates are capable of generating a bright signal in T 1 -weighted MRI images. Such NPs include micelles, polymeric particles and liposomes. However, most T 1 contrast agents have poor relaxivity compared with the T 2 relaxivity of SPIOs. Recently, hollow MnO NPs have been developed as a dual T 1 and T 2 contrast agent. 133 Core-shell T 1 -T 2 dual mode NPs that combine both MnFe 2 O 4 and gadolinium have also been synthesized. 26 It has shown that by separating gadolinium and MnFe 2 O 4 with a silica oxide layer, the NPs could achieve both high T 1 and T 2 relaxivity. Performing both T 1 -and T 2 -weighted imaging could help exclude faulty signals and enhance diagnostic accuracy.
The performance of NP probes as imaging contrast agents is determined by signal-to-noise ratio and detection sensitivity. It is therefore critical to synthesize SPIOs with substantial signal enhancement on a per-particle basis to improve sensitivity, and to tailor NP surface chemistry to optimize the specific accumulation (attachment) of SPIOs in/on diseased cells, tissues or organs. It has been established that T 2 relaxivity of SPIOs increases with the magnetization and the size of iron oxide cores if the total amount of iron is constant. 53, 84 The magnetization of SPIOs can also be enhanced by using cores formed by elementary iron or by doping iron oxide with other magnetic elements such as nickel, cobalt and manganese. 78, 88, 148 Further, the core size of SPIOs can be increased by employing controllable crystallization through thermo-decomposition of iron complex in organic solvents. 79, 148, 167, 174 NPs for Hyperthermia and Magnetic Targeting
In addition to in vivo imaging applications, over the past few years, magnetic NPs have received extensive studies for applications in hyperthermia and magnetic targeting. Magnetic NPs can generate heat in oscillating magnetic field (100 kHz to 1 MHz), which enables hyperthermia in deep tissues. 47, 90, 125 Magnetic targeting has been widely used in various in vitro applications including cell separation, gene transfection and sample enrichment in detection assays. Recent studies have shown that in vivo magnetic targeting can be used for controlled delivery of therapeutic agents and cells, 37, 105 and stem cells and progenitor cells could be labeled with high amount of SPIOs without affecting cell viability and function. 86, 91, 142 Tracking immune cells labeled with SPIOs has been an important approach in detecting atherosclerosis. 141 The magnetic mobility and heating capability of magnetic NPs can also be employed to trigger cellular events in vivo.
25,136
Iron Oxide NP-based Biomolecule Detection
Many biological studies and clinical applications require sensitive detection of biomolecules, including lipids, proteins and nucleotides. Enzyme-linked immunosorbent assay (ELISA) has been the industrial standard for quantification of protein and other macromolecule since its emergence in 1970s. 45, 150 However, enzyme-substrate interaction is subjected to a number of variables such as enzymatic activity and incubation conditions. Biomolecule quantification with enzymelinked probes is hindered by the requirement of stringent control, costly calibration as well as the nonlinear nature of enzymatic catalysis. Recently, the iron oxide NP-linked immunosorbent assay (ILISA) was developed by integrating the dissolution of nanocrystals and metal-induced stoichiometric chromogenesis, exploiting the dense atom packing in metallic nanocrystals. 145 As shown in Fig. 4a , antibody-functionalized wu¨stite (Fe 12x O) nanocrystals are bound to the target molecules (e.g., antigen) in a 96-well assay format. After unbound probes are removed, the nanocrystals are dissolved into individual metal ions that are then converted to chromophores. In ILISA, signal amplification is fully determined by the total number of Fe atoms in the nanocrystals bound to single target molecules. Since each metallic nanocrystal consists of thousands to millions of metal atoms, extremely high signal amplification can be achieved by stoichiometri- cally converting the nanocrystal to chromophores and quantifying them photometrically. Similar to ELISA, direct, indirect, competitive and sandwich ILISA can all be performed with high sensitivity. The signal amplification of ILISA can be further optimized by varying the size and number of nanocrystals bound to an individual analyte molecule. 145 Compared with enzyme-based signal amplification, ILISA provides a simple, highly sensitive and more reliable assay for biomolecule detection, facilitating the quantification of biomolecule concentration and binding kinetics in laboratory settings, and enabling instrument-free evaluation of disease markers for on-site diagnostics. To illustrate, sandwich ILISA was used to detect vascular cell adhesion molecule-1 (VCAM-1) in the lysate of lipopolysaccharide (LPS)-stimulated human umbilical vascular endothelial cells (HUVECs). It was found that VCAM-1 could be detected at low total protein concentrations (1 lg/mL) while achieving a good linearity (Fig. 4b) . Sandwich ILISA was also used to detect a blood coagulation factor factor-X in clinical plasma samples in an instrument-free fashion (Fig. 4c) . The chromogenic reactions can be either solution-based or surface-based and performed in aqueous or organic phase, supporting a variety of assay formats. 127 The nanocrystalbased amplification scheme can also be implemented with a rich selection of metal/metal oxide nanocrystals and metal-reactive chromogenic substrates, thus multiplexable. This NP-based signal amplification scheme adds a new dimension to current NP-based bioassays.
Multifunctional NPs for Combined Imaging and Therapy
For medical applications, it is often desirable to integrate imaging probes and therapeutic agents into one, often referred to as a theranostic agent, to improve efficacy and reduce toxicity. With only a few exceptions, theranostic agents are developed using NP platforms. A typical theranostic NP may have part or all of the following components: (1) an imaging contrast agent, (2) chemical bonds or physical interactions for loading and releasing of drugs or genes, (3) targeting ligands, and (4) elements that respond to external triggers such as ultrasound, light and magnetic field (Fig. 5) . Recent advances in nanomaterials enable the synthesis of NPs with rich physical and chemical properties that facilitate the incorporation of small molecular moieties. Multiple functionalities can be readily integrated using the same NP by modulating its structural and/or chemical compositions. For example, nanocrystals can be readily decorated with different coating strategies, including silica/ mesoporous silica, micelle, liposome and layer-by-layer assembly. These coatings are useful for both physical/ chemical adsorption of small molecules and encapsulation of multiple nanocrystals. Small molecules, including dyes, therapeutic agents and targeting ligands, can be conjugated to NPs at substantial payload ratio using well controlled conjugation chemistry.
There have been a few classes of multifunctional, theranostic NPs developed, including gold NPs and magnetic iron oxide NPs. In addition to be remarkable contrast agents for optical imaging, photoacoustic imaging and CT, 55, 116 gold nanoshells, nanorods, nanocages and nanostars can be employed for photothermal therapies. 63, 69 Recent studies have shown that gold NPs can be heated by non-resonant shortwave radiofrequency fields, which allows targeted hyperthermia in deep tissue. 49 Gold nanocages have also shown great potential as drug carriers for controlled release with NIR light. 172 SPIOs are the most well-studied theranostic NPs owing to their excellent biocompatibility, 159 superior MRI T 2 contrast, 144 magneto-mobility 105 and capability to be heated with an alternating magnetic field. 47 In the past few years, several forms of SPIO-based drug carriers have been developed by modifying iron oxide nanocrystals with various surface coating. For example, it has been shown that mitoxantrone conjugated to starch-coated SPIOs could effectively treat VX-2 squamous cell carcinoma in a rabbit model. 1 In this study, the SPIOs administrated intra-arterially were retained at the tumor site by an electromagnet, thus significantly reducing systemic toxicity. However, drug loading via chemical conjugation is restricted to a small group of drug molecules with reactive moieties. In contrast, iron oxide nanocrystals with micellar coating have great promise as carriers for many small chemotherapeutic drug molecules. 57, 72, 93, 110 In this approach, iron oxide nanocrystals are synthesized with nonpolar capping molecules. Waterdispersible NPs are obtained by coating the nanocrystals with a monolayer of amphiphilic copolymers through hydrophobic interactions. 112, 143 Small hydrophobic molecules such as doxorubicin and paclitaxel can be stored in the hydrophobic layer of micellar coating. NPs with amphiphilic capping molecules covalently bound to iron oxide surface can also adsorb drug molecules by hydrophobic interactions. 40, 129 Another coating with broad drug loading capability is mesoporous silica. 83 Small drug molecules and fluorophores can be loaded into the porous silica shell through either chemical conjugation or electrostatic interactions. Drug loading by hydrophobic or electrostatic interactions often affords much higher loading capacity than that of chemical conjugation. However, drug molecules may be prematurely released from the NPs during systemic circulation. Other major types of magnetic delivery vehicles include liposomes or cerasomes containing iron oxide nanocrystals. 108 SPIOs have also been used as the carriers for in vivo gene delivery. For example, multifunctional NPs were constructed by simultaneously conjugating siRNA, NIR fluorophores (Cy5.5) and cell membrane translocation peptides to dextran coated iron oxide NPs. 97 Tumor accumulation of the NPs was confirmed with both T 2 contrast in MRI and fluorescence imaging, which was in good agreement with the knockdown effects of siRNAs observed. In a similar preparation, siRNA, Cy5 and RGD peptides were conjugated to the surface of MnFe 2 O 4 NPs that possess high T 2 relaxivity. 89 Magnetic liposomes that bound siRNAs by electrostatic interactions were also developed, which inhibited tumor angiogenesis and proliferation by suppressing the expression of EGF receptor in a mouse tumor model. 105 To date, most of the studies in nanomedicine involve the development of NP-based approaches, especially multifunctional NP systems as imaging contrast agents and/or drug/gene delivery vehicles, utilizing a combination of targeting, delivery, reporting (contrast), and physical effector functions. Although still in its infancy, the development of engineered molecular machines has the potential to significantly advance nanomedicine. These molecular machines are typically multicomponent and multifunctional, with target recognition, actuation, manipulation, self-assembly and disassembly functions, enabling the quantification, control and precise modification of biological processes in living cells. Discussed below is a class of molecular machines that perform highly specific modification of DNA sequences in living cells for genome editing applications.
ENGINEERED MOLECULAR MACHINES FOR GENOME EDITING
A major goal of nanomedicine is to enable highly specific medical intervention at the molecular scale for curing disease and/or repairing tissue. To achieve this goal, it is necessary to precisely control and manipulate biomolecules and supramolecular assemblies in living cells, exploiting nature's design of biological machines, pathways and molecular structures.
To date, the most promising molecular machines for nanomedicine applications are engineered nucleases, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and the clustered regularly interspaced short palindromic repeats (CRISPR) systems as powerful tools for genome editing through specifically cleaving genomic sequences. 140, 149, 162 As shown in Fig. 6 , the primary forms of targetable nucleases are ZFNs 117 ( Fig. 6a ) and TALENs 8, 117 ( Fig. 6b) , each containing a DNAbinding domain (zinc finger or TAL effector, respectively) fused to the FokI non-specific DNA cleavage domain. 80 These nucleases can be designed to create a DNA double-strand break (DSB) in a specific (predetermined) target sequence, which can be processed by the cellular DNA repair machinery. The primary means of re-ligation of the DSB is error-prone nonhomologous end joining (NHEJ), which often results in frame-shift mutations that can disrupt a coding sequence of the gene. If a donor DNA template is supplied along with the nucleases, the DSB can be repaired using the homologous recombination (HR) pathway. This process can lead to precise genome editing of the endogenous gene if the supplied donor sequence is designed for a specific purpose, such as gene correction (using wild-type template), gene disruption (inducing mutations and deletions), or adding new gene function (with insertion). In particular, nuclease-induced DSB near a disease-related mutation site can greatly increase the rate of HR that incorporates the supplied donor template, 126 thereby enabling gene correction and the isolation of gene-corrected cells. The high efficiency of genome editing has greatly enhanced the capability to edit genomic sequences for basic research, as well as medical applications.
The specificity of ZFNs and TALENs is greatly increased by the need for binding of a pair of nucleases for cleavage to occur. If a pair of nucleases binds to the two half-sites of a target sequence with the correct orientation and spacing, the FokI domains dimerize, resulting in cleavage of the intervening DNA 6, 135 ( Fig. 6) . A large amount of work in genome editing has been performed using ZFNs, which were developed over a decade ago. For example, ZFNs have been used to modify the genomes of multiple model organisms and human cells. 132 The DNA-binding domains of individual ZFNs typically contain between three and six individual zinc finger repeats; each finger can recognize three DNA bases. To engineer zinc fingers to bind desired sequences, both ''modular assembly'' and selection approaches have been used, and methods have been developed for identifying ZFN target sites 74, 77, 122 or for rational design of ZFNs. 43, 81 However, the use of ZFNs has been significantly hindered by the difficulties in designing zinc fingers that can bind to a specific DNA sequence with high affinity and specificity.
In contrast to ZFNs, TALEN design is greatly simplified due to the straightforward relationship between the protein sequences of TALENs and their DNA targets. 8, 102 Specifically, TALENs contain a series of modular DNA-binding elements (repeats); each~34 amino acid repeat is well conserved and fairly constant except for the two amino acids termed the 'repeat-variable di-residues' (RVDs), which determine the nucleotide specificity of the repeat. RVDs are chosen to specify each nucleotide in the target sites: Asn-Ile (NI) target adenines, His-Asp (HD) target cytosine and Asn-Gly (NG) to target thymines. The most commonly used guanine-targeting RVD, AsnAsn (NN), appears to be less specific compared to RVDs targeting other nucleotides, since it binds both guanine and adenine with similar affinity. Several alternative guanine-targeting RVDs have thus been studied to increase the target specificity. 27, 30, 137 Assembling TALENs was a challenge due to their repetitive nature and the large size of the genes, until a number of methods were developed that allow highthroughput TALEN construction. 123, 130, 157 In addition to being easier to design, TALENs appear to be superior to ZFNs in other aspects. Largescale experiments confirmed a success rate significantly higher than that for ZFNs, with 88% of the TALENs constructed showing detectible cleavage activity. 123 TALENs can bind to a wide range of sequences with high affinity, whereas ZFNs only target G-rich sequences well. TALEN target sites are longer than ZFN target sites and therefore may result in lower levels of off-target activity (although this has not been well studied). Cells transfected with TALEN plasmids appear to have less cytotoxicity than those with ZFNs, possibly due to lower off-target cleavage. 103, 123, 128 One potential issue with TALENs is their large size, which may limit their delivery by viral-based vectors or nucleofection. It is likely that TALENs will enjoy a wide range of applications due to the ease of design, high success rate and activity, and low off-target effect and cytotoxicity compared with ZFNs. 132 The successful application of custom designed, engineered nucleases for treating human diseases requires identification of the possible off-target cleavage events (cleavage at sites other than the intended target site), which can lead to point mutations, deletions, insertions or chromosomal rearrangements. 34, 164 To date only very limited studies on nuclease off-target cleavage have been performed, revealing that both ZFNs and TALENs have off-target cleavage, as identified by detecting NHEJ directed mis-repair at putative sites, 33 or through methods monitoring DNA breaks or cytotoxicity. 32, 103 Several methods have been introduced to improve the specificity of pairs of custom nucleases. The first is the modification of the FokI domains to require that dimerization only occurs with one ''left'' and one ''right'' nuclease hetero-dimerizing. 42, 100, 140 This method can potentially eliminate cleavage at homodimeric off-target sites that allow either two left or two right nucleases to bind, dimerize and cut. The rate of NHEJ was also greatly reduced through the use of nuclease pairs where one of the two nucleases (a ''nickase'') contains a mutation that renders it catalytically inactive, resulting in single-stranded breaks (nicks) as opposed to DSBs. The decrease in NHEJ could lead to an increase in the ratio of HR to NHEJ, which is advantageous in gene correction applications. However, the ''nickases'' typically have a decreased HR activity compared to wild-type nucleases. 121 There are many potential medical applications of engineered nucleases, including the establishment of HIV-1 resistance in CD4+ T cells by genome editing, 114 and correcting genetic defects (including mutations, deletions or insertions) in treating single-gene disorders. An example is ZFN/TALEN based treatment of sickle cell disease (SCD). SCD is predominantly caused by a single (A-T) mutation in the beta-globin gene and is a painful and life shortening disease that afflicts primarily persons of African ancestry. 115 To use engineered nuclease to treat SCD, it will be necessary to design and optimize ZFNs or TALENs that bind specifically to the beta-globin gene, and deliver them, as well as donor templates containing the normal (healthy) beta-globin DNA sequence, into the nuclei of hematopoietic stem and progenitor cells (HSPCs). The nucleases introduce a DSB or a nick at the targeted site near the beta-globin locus, which will stimulate the HR pathway to incorporate the donor sequence for gene correction. 5, 61, 138 The autologous gene-corrected HSPCs can then be re-engrafted in the SCD patient to produce healthy red blood cells and replace sickle cells. HSPCs are the normal precursors of all blood cells, including the oxygencarrying erythrocytes rendered dysfunctional in sickle cell patients. These cells are relatively rare in the body, but possess potent regenerative potential in that transplantation of a small amount of HSPCs is sufficient to rebuild the entire blood system of an organism. Thus, by isolating HSPCs that carry the sickle mutation, correcting this mutation ex vivo, and then transplanting the gene-corrected HSPCs back into affected recipients, it will be possible to provide enduring replacement of the blood-producing cells of SCD patients with unaffected precursors, thereby supplying healthy red blood cells and effectively curing the disease.
Although the gene correction approach for treating SCD rests on established scientific principles without any conceptual barrier to its implementation, there are many practical and technological challenges in translating the nuclease-based gene correction approach to clinical practice. These include shifting repair pathway choice from NHEJ toward HR, 5 increasing the spontaneous rate of gene correction by many orders of magnitude, identifying and minimizing unwanted offtargeting effects and gene rearrangements, and establishing a high-throughput, high efficiency delivery capability. These challenges can be overcome by optimizing nuclease and donor template designs, 35 exploring alternative delivery methods, and applying novel imaging probes and methods to observe and systematically optimize each step in the gene correction process. It is likely that the methods and technologies developed in nuclease-based SCD treatment can be applied to treating other diseases. It has been estimated that there are~1,0000 human single-gene disorders, which impose a significant burden on human health worldwide. Indeed, several of these diseases have already been corrected using nuclease technology in vitro; single point mutations causing epidermolysis bullosa, 109 a 1 -antitrypsin deficiency, and inactive versions of the p53 tumor suppressor protein, 62 as well as the three basepair deletion causing most forms of cystic fibrosis (D508) 87 have all been repaired using ZFNs or TALENs. Therefore, the development of nanomedicine approaches for treating single-gene disorders based on engineered nucleases may have a significant impact to human health.
The recent discovery of a bacterial defense system that uses RNA-guided DNA cleaving enzymes and CRISPR 9, 51, 59, 66, 96 (Fig. 6c) are an exciting alternative to ZFNs and TALENs. CRISPR systems provide a form of acquired immunity in bacteria against previously seen foreign DNA via RNA-guided DNA cleavage. 160 Type II CRISPR/Cas systems are comprised of short segments of foreign DNA ('spacers') integrated within the CRISPR genomic loci. When these sequences are transcribed and processed into short RNAs, they guide the cleavage of specific DNA sequences.
Unlike ZFNs and TALENs, the CRISPR-associated (Cas) protein remains the same for different gene targets; only the short sequence of the guide RNA needs be changed to redirect the site-specific cleavage of novel sequences. 31 With the matching guide RNA, a Type II CRISPR/Cas system is able to target a 19 nt genomic sequence immediately before a required protospacer adjacent motif (PAM). In stark contrast to ZFNs and TALENs, CRISPR guide strands are very simple to clone, and allow testing within days. When cleavage is directed by the short RNA sequences of the guide strands, the target sites are limited to~23 bp sequences including the PAM. Although CRISPR/Cas induced DNA cleavage was initially thought to be fairly specific, off-target cleavage was found to occur in endogenous gene sequences with up to five mismatches to the guide strands, though mismatches close to or inside the PAM were less tolerated. 34, 48, 68 Recent experiments targeting HBB with CRISPR exemplify many of these features. 34 Specifically, eight pairs of oligonucleotides were cloned into the Cas9 expression vector, allowing efficient cleavage of HBB, as quantified by NHEJ mutagenesis rate (Fig. 7) . The average HBB mutation rate was 54%, but there was significant off-target cleavage, especially at similar sites in hemoglobin delta (HBD). Off-target cleavage results in mutagenesis and can lead to chromosomal rearrangements, as demonstrated by the R-03 guide strand with high on-and off-target cleavage rates. In cells transfected with this CRISPR system, the region between HBB and HBD was deleted in 13% of the chromosomes. In some cases, transfecting lower levels of the CRISPR plasmids resulted in decreased levels of off-target cleavage. 34, 48 The full extent of CRISPR offtarget cleavage, however, has yet to be determined. Recent results suggest that it is difficult to identify sequences with no off-target cleavage in a mammalian genome due to the tolerance of up to 5 mismatches in ã 23-bp sequence. 94 New methods to determine the possible off-target cleavage sites need be developed in hopes of monitoring and improving specificity. A new study using paired CRISPR/Cas9 nickases for generating DSBs may be a promising way to increase the specificity, though the off-target effects for this nickase system still need to be further investigated. 94 
OPPORTUNITIES AND CHALLENGES IN NANOMEDICINE
Nanomedicine research and development that utilize nano-scale (1-100 nm) features of materials and structures at atomic, molecular and macromolecular levels have the potential to provide fundamental understanding of biological processes in living cells that would be otherwise unthinkable, establish the ability to precisely measure, control and manipulate the functions of biomolecules in vivo, and create medical reagents, devices and systems that have novel properties and functions because of their nano-scale features. For example, the diagnosis and treatment of atherosclerosis represents an area where targeted NPs have great potential for noninvasive diagnosis, targeted therapy, and plaque stabilization. Specifically, it is possible to have nano-scale multifunctional devices that could detect thrombotic events in vivo and deliver therapeutic agents such as anticoagulants as needed. Therapeutic NPs have the potential for curing inflammatory lung diseases, including biodegradable nano-and microparticles releasing anti-oxidant and anti-inflammatory drug molecules, and NPs capable of sensing alveolar function and releasing drugs only when needed, restricting drug delivery to affected areas in heterogeneous disease conditions. Nanomedicine approaches may enable early detection of cancer, and the targeted delivery of anticancer drugs into tumor tissue, dramatically increasing their efficacy and decreasing the side-effects. NP based imaging probes may enable us to detect cancer stem cells and reveal the interaction between normal and cancer cells during the earliest stages of the cancer development, thus having the potential to eliminate death and suffering from cancer.
To successfully develop nanomedicine as a new field, there are significant challenges in achieving high efficacy and safety, and in technology translation and commercialization. Some of the major challenges in these areas are summarized in Table 1 . Clearly, for nanomedicine to generate a large clinical impact, it has to produce methods, devices, drugs, procedures, tools or reagents that are better than existing counterparts, such as simpler, faster, cheaper or safer; more sensitive, specific or robust; or having entirely new functionalities. Achieving these will require concerted efforts by researchers in nano-science, nano-engineering, biology, chemistry, medicine as well as experts in manufacturing, commercialization, regulation, safety, and environmental protection.
Although NP-based contrast agents for MRI or combined MR/PET imaging have a great potential, there are also significant challenges in translating the nanotechnology into clinical use. Clearly, the NP probes must have good biocompatibility and minimal toxicity. 176 The clearance of NPs from the body, if they are not biodegradable, is a very important aspect. It is also essential to have a sufficient accumulation of NPs inside (or on the surface) of diseased cells, tissues (such as tumor) or organs in order to generate a high enough signal-to-noise ratio in disease detection. Achieving a good balance among sensitivity, signal-to-noise ratio and safety, the size, functionalization (the type and amount of targeting ligand), surface chemistry (coating, reporters) and the total amount of contrast agent delivered need to be optimized.
To effectively develop nanomedicine, we must take a systems approach in addressing the major challenges. For example, for NPs as an in vivo imaging contrast agent, the size and surface chemistry of NPs need to be tailored to achieve optimal sensitivity, signal-to-noise, biodistribution, and the amount required in a well-balanced fashion. Similarly, for NP-based in vivo drug/gene delivery, the nano-carriers need to be well designed to achieve adequate cargo loading, controlled release, specific organ/cell internalization and accumulation, and quick clearance/ degradation of the NPs. For disease treatment using engineered nucleases, it is necessary to optimize the design of ZFNs, TALENs or CRISPR/Cas9 systems so that both high gene correction efficiency and minimal off-target effect can be realized. Most of the nanomedicine approaches involve cellular and/or in vivo delivery of NPs, proteins, DNA/RNA or drug molecules, which is a common challenge, therefore requires a systematical study. To commercialize nanotechnologies for medical applications, new FDA policies, regulations and guidelines are being developed in the US and the rest of the world, Despite the significant challenges and regulatory barriers in developing nanomedicine and its commercialization, a huge progress has been made in nanomedicine over the last 10 years and many nanotechnology related clinical trials have been, or are being, conducted. Many commercial products based on nanomedicine approaches have emerged, and will continue to emerge, which may significantly impact on all areas of medicine. Nanomedicine will dramatically exceed what has occurred to date in the history of medicine, and will likely revolutionize medicine.
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